Clinical outcomes of First-line Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Deprivation Therapy (ADT) + Docetaxel (D) or ADT alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

BACKGROUND: The CHAARTED and STAMPEDE trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abirater...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Genitourin Cancer
Main Authors: Francini, Edoardo, Yip, Steven, Ahmed, Shubidito, Li, Haocheng, Ardolino, Luke, Evan, Carolyn P., Kaymakcalan, Marina, Shaw, Grace K., Kantoff, Philip W., Taplin, Mary-Ellen, Alimohamed, Nimira S., Joshua, Anthony M., Heng, Daniel Y. C., Sweeney, Christopher J.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986287/
https://ncbi.nlm.nih.gov/pubmed/29331381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.12.012
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker